JP2013518038A5 - - Google Patents

Download PDF

Info

Publication number
JP2013518038A5
JP2013518038A5 JP2012549377A JP2012549377A JP2013518038A5 JP 2013518038 A5 JP2013518038 A5 JP 2013518038A5 JP 2012549377 A JP2012549377 A JP 2012549377A JP 2012549377 A JP2012549377 A JP 2012549377A JP 2013518038 A5 JP2013518038 A5 JP 2013518038A5
Authority
JP
Japan
Prior art keywords
nhc
alkyl
conjugate according
valence bond
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012549377A
Other languages
English (en)
Japanese (ja)
Other versions
JP5875527B2 (ja
JP2013518038A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/050923 external-priority patent/WO2011089255A1/en
Publication of JP2013518038A publication Critical patent/JP2013518038A/ja
Publication of JP2013518038A5 publication Critical patent/JP2013518038A5/ja
Application granted granted Critical
Publication of JP5875527B2 publication Critical patent/JP5875527B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012549377A 2010-01-22 2011-01-24 ｉｎ−ｖｉｖｏにおける効力が延長された成長ホルモン Active JP5875527B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29730510P 2010-01-22 2010-01-22
EP10151405 2010-01-22
EP10151405.7 2010-01-22
US61/297,305 2010-01-22
PCT/EP2011/050923 WO2011089255A1 (en) 2010-01-22 2011-01-24 Growth hormones with prolonged in-vivo efficacy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015209720A Division JP2016026204A (ja) 2010-01-22 2015-10-26 ｉｎ−ｖｉｖｏにおける効力が延長された成長ホルモン

Publications (3)

Publication Number Publication Date
JP2013518038A JP2013518038A (ja) 2013-05-20
JP2013518038A5 true JP2013518038A5 (enExample) 2014-03-06
JP5875527B2 JP5875527B2 (ja) 2016-03-02

Family

ID=42075933

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012549377A Active JP5875527B2 (ja) 2010-01-22 2011-01-24 ｉｎ−ｖｉｖｏにおける効力が延長された成長ホルモン
JP2015209720A Pending JP2016026204A (ja) 2010-01-22 2015-10-26 ｉｎ−ｖｉｖｏにおける効力が延長された成長ホルモン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015209720A Pending JP2016026204A (ja) 2010-01-22 2015-10-26 ｉｎ−ｖｉｖｏにおける効力が延長された成長ホルモン

Country Status (20)

Country Link
US (5) US9695226B2 (enExample)
EP (1) EP2525834B1 (enExample)
JP (2) JP5875527B2 (enExample)
KR (1) KR101813595B1 (enExample)
CN (6) CN118767115A (enExample)
AU (1) AU2011208625C1 (enExample)
BR (1) BR112012018116B1 (enExample)
CA (1) CA2787890C (enExample)
FI (1) FIC20210013I1 (enExample)
FR (1) FR21C1029I2 (enExample)
HU (1) HUS2100029I1 (enExample)
IL (1) IL220605A (enExample)
MX (2) MX345736B (enExample)
NO (1) NO2021023I1 (enExample)
PL (1) PL2525834T3 (enExample)
RS (1) RS59459B1 (enExample)
RU (1) RU2605627C2 (enExample)
SI (1) SI2525834T1 (enExample)
TW (1) TWI508737B (enExample)
WO (1) WO2011089255A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2461831B1 (en) * 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Growth hormones with prolonged in-vivo efficacy
CN118767115A (zh) 2010-01-22 2024-10-15 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
CN108524919A (zh) 2012-05-17 2018-09-14 延伸生物科学股份有限公司 用于改进的药物递送的载体
US20150250882A1 (en) * 2012-10-17 2015-09-10 Novo Nordisk Health Care Ag Fatty Acid Acylated Amino Acids for Growth Hormone Delivery
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
WO2015036553A1 (en) 2013-09-16 2015-03-19 Novo Nordisk Health Care Ag Thiol functionalized polymers
ES2869309T3 (es) * 2013-12-13 2021-10-25 Novo Nordisk Healthcare Ag Método para la conjugación de proteínas con tioéter
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
CA2972871A1 (en) * 2015-01-23 2016-07-28 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
US10654912B2 (en) 2015-09-08 2020-05-19 Jcr Pharmaceuticals Co., Ltd. Human serum albumin mutant
JP2018527360A (ja) 2015-09-22 2018-09-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 修飾された細胞毒とその治療的使用
US10286079B2 (en) 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
JP2017165713A (ja) 2016-03-14 2017-09-21 Ｊｃｒファーマ株式会社 血清アルブミン−２０ｋ成長ホルモン融合タンパク質
EP4047006A4 (en) 2019-10-17 2023-11-01 JCR Pharmaceuticals Co., Ltd. Method for producing fusion protein of serum albumin and growth hormone
CN114728043B (zh) 2019-10-30 2024-04-16 Jcr制药股份有限公司 含有血清白蛋白与生长激素的融合蛋白的水性药物组合物
CN115960246A (zh) * 2021-10-13 2023-04-14 北京志道生物科技有限公司 一种重组环状人生长激素-Fc融合蛋白及其应用
IL319526A (en) 2022-09-30 2025-05-01 Extend Biosciences Inc Long-acting parathyroid hormone
CN115845079B (zh) * 2022-11-24 2023-07-18 武汉禾元生物科技股份有限公司 一种重组人血清白蛋白与重组人生长激素的偶联物及其制备方法
KR20250117684A (ko) * 2023-05-12 2025-08-05 노보 노르디스크 에이/에스 지속성 성장 호르몬 수용체 길항제 및 이의 용도
CN118955671A (zh) * 2023-05-15 2024-11-15 上海多米瑞生物技术有限公司 补体抑制剂及其制备方法和用途

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8504099D0 (en) 1985-02-18 1985-03-20 Wellcome Found Physiologically active substances
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8610551D0 (en) 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
JPH0665280B2 (ja) 1987-03-04 1994-08-24 味の素株式会社 タンパクゲル化剤及びそれを用いるタンパクのゲル化方法
ES2154627T3 (es) 1988-08-24 2001-04-16 American Cyanamid Co Estabilizacion de somatotropinas mediante la modificacion de restos de cisteina utilizando mutagenesis de localizacion dirigida o derivatizacion quimica.
US5079230A (en) 1988-09-12 1992-01-07 Pitman-Moore, Inc. Stable bioactive somatotropins
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
DE68929151T2 (de) 1988-10-28 2000-07-20 Genentech, Inc. Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten
JPH04504246A (ja) 1989-03-20 1992-07-30 ザ・ジェネラル・ホスピタル・コーポレーション インシュリン刺激ホルモン
US5101018A (en) 1989-06-12 1992-03-31 International Minerals & Chemical Corp. Method for recovering recombinant proteins
DE3930696A1 (de) 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
CA2073856C (en) 1990-01-24 2002-12-03 Douglas I. Buckley Glp-1 analogs useful for diabetes treatment
DK0458064T3 (da) 1990-05-04 1998-04-27 American Cyanamid Co Stabilisering af somatotropiner ved modificering af cysteinrester
US5951972A (en) 1990-05-04 1999-09-14 American Cyanamid Company Stabilization of somatotropins and other proteins by modification of cysteine residues
JP2849773B2 (ja) 1990-08-27 1999-01-27 天野製薬株式会社 ストレプトミセス属由来のトランスグルタミナーゼの製造法
DK220890D0 (da) 1990-09-14 1990-09-14 Ole Buchardt Fremgangsmaade til fremstilling af c-terminalt amiderede peptider
JP3267293B2 (ja) 1990-12-03 2002-03-18 ジェネンテク，インコーポレイテッド 改変された結合性を有する変異タンパク質の豊富化法
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
IT1251895B (it) 1991-09-27 1995-05-26 Eniricerche Spa Mutanti dell'ormone della crescita umano e loro impiego
EP0555649B1 (en) 1992-01-14 2004-12-08 Ajinomoto Co., Inc. Gene encoding transglutaminase derived from fish
DE69334134T2 (de) 1992-07-31 2007-12-20 Genentech, Inc., South San Francisco Wässrige Formulierung enthaltend Menschliches Wachstumshormon
ZA936811B (en) 1992-10-28 1995-03-15 Upjohn Co Somatotropin modifications
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
JP3758187B2 (ja) 1994-01-28 2006-03-22 味の素株式会社 マガキ由来のトランスグルタミナーゼ
WO1996006931A1 (en) 1994-08-26 1996-03-07 Novo Nordisk A/S Microbial transglutaminases, their production and use
CN1165539A (zh) 1994-09-29 1997-11-19 味之素株式会社 肽及蛋白质的修饰
DE4437604A1 (de) 1994-10-21 1996-04-25 Basf Ag Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
DE69629719T2 (de) 1995-01-19 2004-07-08 Novozymes A/S Transglutaminasen aus oomyzeten
JP3669390B2 (ja) 1995-02-09 2005-07-06 味の素株式会社 バチルス属細菌由来のトランスグルタミナーゼ
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
CA2658039A1 (en) 1995-09-21 1997-03-27 Genentech, Inc. Human growth hormone variants
US20020077461A1 (en) 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
CZ300837B6 (cs) 1996-08-30 2009-08-26 Novo Nordisk A/S Deriváty GLP-1(7-37) nebo jeho analogy, farmaceutický prostredek je obsahující a jejich použití
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
JP2000517308A (ja) 1996-08-30 2000-12-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―２誘導体
CN1231675A (zh) 1996-09-26 1999-10-13 味之素株式会社 修饰的生理活性蛋白及含有该蛋白的药物组合物
US5985627A (en) 1997-02-28 1999-11-16 Carlsberg Laboratory Modified carboxypeptidase
JPH1156378A (ja) 1997-06-11 1999-03-02 Nippon Chem Res Kk 変異型ヒト成長ホルモンとその用途
US8530190B1 (en) 1997-06-25 2013-09-10 Merck Serono Sa Disulfide crosslinked glycoprotein hormone analogs, and their preparation and use
DE69838552T2 (de) 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
JPH1192499A (ja) 1997-09-22 1999-04-06 Sumitomo Pharmaceut Co Ltd ヒト成長ホルモン変異体
US6136536A (en) 1997-10-29 2000-10-24 Genetics Institute, Inc. Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
DE69916811T2 (de) 1998-02-27 2005-04-14 Novo Nordisk A/S Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden
WO1999043705A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
EP1060192A2 (en) 1998-02-27 2000-12-20 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
EP1062240B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S N-terminally modified glp-1 derivatives
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
US6656922B2 (en) 1998-05-28 2003-12-02 Mediplex Corporation, Korea Oral delivery of macromolecules
US6358705B1 (en) 1998-07-16 2002-03-19 Novo Nordisk A/S Method of making proteins in transformed yeast cells
RU2214418C2 (ru) 1998-12-07 2003-10-20 Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик Сас Аналоги glp-1
CN1191273C (zh) 1999-05-17 2005-03-02 康久化学公司 长效促胰岛肽
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
AU5805500A (en) 1999-07-07 2001-01-30 Maxygen Aps A method for preparing modified polypeptides
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
GB2355009A (en) 1999-07-30 2001-04-11 Univ Glasgow Peptides conjugated to bile acids/salts
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
JP2003519664A (ja) 2000-01-11 2003-06-24 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１誘導体の経上皮送達
DE60138364D1 (de) 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
AU2001261024A1 (en) 2000-04-12 2001-10-30 Delta Biotechnology Limited Albumin fusion proteins
AU2001274853B2 (en) 2000-05-16 2007-03-22 Bolder Biotechnology, Inc. Methods for refolding proteins containing free cysteine residues
US20020142964A1 (en) 2000-11-02 2002-10-03 Nissen Torben Lauesgaard Single-chain polypeptides
MXPA03005036A (es) 2000-12-07 2003-09-05 Lilly Co Eli Proteinas de fusion glp-1.
US20060183197A1 (en) * 2001-01-11 2006-08-17 Andersen Kim V Variant growth hormone molecules conjugated with macromolecules compounds
AU2002219021A1 (en) * 2001-01-11 2002-07-24 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds
FR2819810B1 (fr) 2001-01-23 2004-05-28 Pf Medicament Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
EP2110385A1 (en) 2001-06-14 2009-10-21 The Scripps Research Institute Stabilized factor VIII with engineered disulfide bonds
WO2003002136A2 (en) 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
US7186797B2 (en) 2001-08-10 2007-03-06 Epix Pharmaceuticals, Inc. Polypeptide conjugates with extended circulating half-lives
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
WO2003042245A2 (en) 2001-11-12 2003-05-22 University Of Wales College Of Medicine Growth hormone variations in humans and their uses
JP2005525302A (ja) 2001-11-20 2005-08-25 ファルマシア・コーポレーション 化学的に修飾されたヒト成長ホルモンコンジュゲート
JP2003199569A (ja) 2001-12-17 2003-07-15 Food Industry Research & Development Inst ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ
FR2836382B1 (fr) 2002-02-28 2004-08-13 Biomerieux Sa Nouveaux agents de couplages, leurs conjugues, ainsi que l'utilisation de ces conjugues dans des methodes de diagnostic
EP1587944A4 (en) 2002-03-01 2007-03-21 Dyax Corp KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
NZ535684A (en) 2002-04-10 2006-03-31 Lilly Co Eli Use of a GLP-1 (glucagon like peptide-1) compound to treat gastroparesis by increasing gastric emptying
CN101942019A (zh) 2002-04-30 2011-01-12 拜耳医药保健有限公司 凝血因子VII或VIIa多肽变体
ATE466085T1 (de) 2002-09-09 2010-05-15 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
CA2513307A1 (en) 2003-02-19 2004-09-02 Zheng Xin Dong Analogues of glp-1
EP1625158A2 (en) 2003-05-09 2006-02-15 Novo Nordisk A/S Peptides for use in treating obesity
EP1654004A2 (en) 2003-08-08 2006-05-10 Novo Nordisk A/S Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
TW200526254A (en) * 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
JP2007537981A (ja) 2003-09-19 2007-12-27 ノボ　ノルディスク　アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
RU2401276C2 (ru) 2003-09-19 2010-10-10 Ново Нордиск А/С Производные глюкагон-подобного пептида-1 (glp-1)
CN100444898C (zh) * 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
EP1673464A2 (en) 2003-10-10 2006-06-28 Novo Nordisk A/S Conjugation of peptides
KR20060135661A (ko) 2003-12-18 2006-12-29 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 화합물
KR20060109940A (ko) 2003-12-18 2006-10-23 노보 노르디스크 에이/에스 알부민-유사제에 연결된 신규 ｇｌｐ-1 유사체
US20070105770A1 (en) 2004-01-21 2007-05-10 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
RU2385879C2 (ru) 2004-01-21 2010-04-10 Ново Нордиск Хелс Кеа Аг Способ конъюгации пептидов, опосредованной трансглутаминазой
NZ548255A (en) 2004-02-02 2010-10-29 Ambrx Inc Modified human interferon polypeptides and their uses
EP1740213B9 (en) 2004-04-07 2012-06-13 Ares Trading S.A. Liquid growth hormone formulation
US7906137B2 (en) 2004-05-21 2011-03-15 Mediplex Corporation, Korea Delivery agents for enhancing mucosal absorption of therapeutic agents
EP1765408B1 (en) 2004-07-08 2015-12-09 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
JP2008507990A (ja) 2004-08-02 2008-03-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｆｖｉｉの抱合体
JP2008515856A (ja) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 遅延性ｇｌｐ−１化合物
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
NZ555386A (en) 2004-12-22 2011-01-28 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid
JP2008533104A (ja) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１受容体の二量体ペプチドアゴニスト
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
MX2007011307A (es) 2005-03-18 2007-10-08 Novo Nordisk As Compuestos de glp-1 extendidos.
EP1893239A2 (en) 2005-06-15 2008-03-05 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of growth hormone
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
EP1919946A1 (en) 2005-08-18 2008-05-14 Novo Nordisk Health Care AG Transglutaminase variants with improved specificity
KR20080038391A (ko) 2005-08-30 2008-05-06 노보 노르디스크 헬스 케어 악티엔게젤샤프트 페그화 성장 호르몬의 액체 제제
CN1939534B (zh) 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
US20090093405A1 (en) 2006-01-19 2009-04-09 Ambrx, Inc. Non-Natural Amino Acid Polypeptides Having Modified Immunogenicity
US20090082254A1 (en) 2006-02-14 2009-03-26 Novo Nordisk A/S Coupling of Polypeptides at the C-Terminus
CA2655188A1 (en) * 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag New protein conjugates and methods for their preparation
CA2672267C (en) 2006-07-27 2016-05-31 Emisphere Technologies, Inc. Arylsulfanyl compounds and compositions for delivering active agents
JP2010500885A (ja) 2006-08-18 2010-01-14 ノボ ノルディスク ヘルス ケア アーゲー 改善された特異性を有するトランスグルタミナーゼ変異体
US20080095837A1 (en) 2006-08-31 2008-04-24 Emisphere Technologies, Inc. Human growth hormone formulations
PL2059260T3 (pl) 2006-08-31 2014-03-31 Novartis Ag Kompozycja farmaceutyczna obejmująca hGH do dostarczania doustnego
EP2129218B1 (en) 2007-02-16 2016-10-19 Emisphere Technologies, Inc. Compounds having a cyclic moiety and compositions for delivering active agents
GB0716328D0 (en) 2007-08-21 2007-10-03 Univ Bath Detection and functionalisation of S-nitrosylated polypeptides
ES2532116T3 (es) 2007-09-05 2015-03-24 Novo Nordisk A/S Péptidos derivados con A-B-C-D y sus usos terapéuticos
US8865868B2 (en) 2008-08-06 2014-10-21 Novo Nordisk Healthcare Ag Conjugated proteins with prolonged in vivo efficacy
EP2324056A1 (en) 2008-09-09 2011-05-25 Novo Nordisk Health Care AG Growth hormone conjugate with increased stability
CN106317164A (zh) * 2008-09-12 2017-01-11 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
JP5816097B2 (ja) 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
WO2010102886A1 (en) 2009-02-19 2010-09-16 Novo Nordisk A/S Modification of factor viii
EP2461831B1 (en) 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Growth hormones with prolonged in-vivo efficacy
CN118767115A (zh) 2010-01-22 2024-10-15 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
EP2536434B1 (en) 2010-02-16 2016-04-20 Novo Nordisk A/S Purification method
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate

Similar Documents

Publication Publication Date Title
JP2013518038A5 (enExample)
RU2012134975A (ru) Гормоны роста с пролонгированной эффективностью in vivo
TW304193B (enExample)
JP2010525122A5 (enExample)
JP2013210627A5 (enExample)
JP2011530500A5 (enExample)
JP2009523146A5 (enExample)
WO2009074535A3 (de) Verfahren zur herstellung von disubstituierten imidazoliumsalzen
RU2012138259A (ru) Способ получения ривароксабана
RU2011136250A (ru) Низкомолекулярное полисульфатированное производное гиалуроновой кислоты и содержащее его лекарственное средство
JP2015227339A (ja) ハロゲン化環式化合物の合成方法
JP2010524927A5 (ja) 化合物２−ヒドロキシ−３−［５−（モルホリン−４−イルメチル）ピリジン−２−イル］１ｈ−インドール−５−カルボニトリルの新規な製造方法
TWI572583B (zh) 含硫醚的（甲基）丙烯酸酯衍生物及含有該衍生物的貼附性改善劑
WO2010007318A3 (fr) NOUVEAUX DERIVES IMIDAZO[1,2-a]PYRIMIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
TW201534592A (zh) 含硫醚的（甲基）丙烯酸酯衍生物及含有該衍生物的貼附性改善劑
JP2014521746A5 (enExample)
JP2018502174A5 (enExample)
CY1109678T1 (el) Νεα παραγωγα 3-φαινυλπροπιονικου οξεος και χρηση αυτων ως συνδετηρες του υποδοχεα ppar-γαμμα
JP2010235601A5 (enExample)
JP2005527479A5 (enExample)
EP3090984A1 (en) Method for preparation of the salts of certain amines and bis(fluorosulfonyl)-imide
JP5668369B2 (ja) チオエーテル含有アルコキシシラン誘導体、およびその用途
JP2018115129A5 (enExample)
JP2004233661A5 (enExample)
RU2016134357A (ru) Конъюгаты фактора viii